Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Pharmacy Benefit Managers (PBMs)
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Display Only
Showing 1216 Results
NPC Chief Science Officer Robert Dubois to Address Value in Personalized Medicine at 13th Annual Personalized Medicine Conference
At the 13th Annual Personalized Medicine Conference, hosted by the Personalized Medicine Coalition, NPC's Dr. Robert W. Dubois will explore why health care stakeholder viewpoints on the value of a…
IVI Introduces Transparent Approach for Value Assessment
The Innovation and Value Initiative (IVI) released its first assessment of treatments for rheumatoid arthritis using its new approach toward value assessment. NPC is still evaluating IVI’s new…
Where Are They Now: Checking In With Former NPC Fellow Chuck Shih
Chuck Shih, PhD, MHS, currently Senior Officer, Drug Spending at Pew Charitable Trusts, was the 2013-2015 NPC Health Policy Fellow as part of a partnership with the George Washington University…
Considerations When Using ICER's Value Assessments
This week we read with great interest an article posted on the Health Affairs Blog that directly responded to National Pharmaceutical Council Chief Science Officer Dr. Robert Dubois’ Sept. 17…
Toward Better Value
There is a disconnect between the important role employers believe their pharmacy benefit managers (PBMs) play in helping to manage prescription drug benefits and employers’ perceptions of the…
When and How is Real-World Evidence Useful in Payer Decision-Making?
Research published in Value in Health from the National Pharmaceutical Council and the University of Arizona School of Pharmacy sheds more light on how real-world evidence is used in decision-making…
Real-World Evidence: Useful in the Real World of United States Payer Decision-Making? How? When? And What Studies?
Research published in Value in Health on real-world evidence provides a deeper understanding of when and how managed care organizations use RWE in decision-making, and how to increase its use.
What’s Contributing to Unnecessary Health Spending?
Reducing low-value care—health care that is cost-inefficient and clinically ineffective—remains a front burner issue for health care stakeholders. It hasn’t been easy to root out or measure low-value…
NPC Talks Value, Benefit Design at AMCP Research Symposium and Nexus 2017
The National Pharmaceutical Council (NPC) is pleased to be participating in next week’s Academy of Managed Care Pharmacy (AMCP) Nexus 2017 meeting in Dallas, Texas. As a sponsor of and participant in…
NPC in AJPB: Guiding Practices for Patient-Centered Value Assessment
In response to growing concerns about health care costs, during the past few years, we’ve seen an increase in the development and use of value assessment frameworks. A variety of physician, payer and…
Why the VA Should Proceed with Caution on ICER Collaboration
In a new blog published by Health Affairs, NPC Chief Science Officer and Executive Vice President Robert W. Dubois, MD, PhD, expands on our initial thoughts on the collaboration between the Institute…
Understanding Real-World Evidence
NPC explores the benefits and challenges with the use of real-world evidence in this first article in a series on this topic.
Appropriate Value Assessment Entails A Broad Perspective Of Impact and A Comprehensive Use of Evidence
NPC Chief Science Officer and Executive Vice President Robert W. Dubois looks at recent publications that highlight the need to consider a societal perspective when assessing value and utilize real…
NPC in Chain Drug Review: Should Patients With the Same Condition Bear Different Costs?
NPC President Dan Leonard tackles variable copays in his latest commentary for Chain Drug Review. In it, he considers when variable cost-sharing is less acceptable for patients who require higher…
What Kinds of Information Do Payers and Providers Want for Decision-Making?
A new white paper from Xcenda/AmerisourceBergen and NPC highlights survey findings from payers and providers on what types of evidence are most important to them when it comes to making population…
Information Wanted: Finding the Balance in Pharmaceutical Evidence Exchange With Payers and Providers
Payers and providers were surveyed to understand the type of health care economic information (HCEI) they desire and value in the current and future health care environment, as well as the potential…
Making Real-World Evidence “Real” for Patients
As real-world evidence (RWE) becomes more broadly used in health care, it’s important to ensure that patients understand what RWE is, determine and address the questions and concerns patients…